Spectra Medical, XL Precision Technologies Announce Rebrand

Spectra Medical Devices (Spectra) and XL Precision Technologies (XLPT) announced a newly combined brand presence— Elevaris Medical Devices. The contract development and manufacturing organization (CDMO) leverages a legacy of excellence to usher in a new era of precision medical device development and manufacturing capabilities.

Spectra’s acquisition of XLPT, announced in September 2024 by healthcare technology and services investor QHP Capital, brought together the companies’ complementary strengths in servicing medical device manufacturers from large-scale OEMs to startups. Spectra provides engineering and manufacturing services as well as technical customer support to OEMs while XLPT offered specialty manufacturing expertise in precision micro-components, complex tubular components, and sub-assemblies.

Today’s announcement marks the formal evolution to a unified brand that honors the each company’s history and embodies their combined commitment to providing deep knowledge, a collaborative approach, and extensive precision manufacturing capabilities to customers worldwide. The decision to establish a new company name and brand identity reflects the promise to apply the best practices and strengths of the individual brands while also emphasizing a singular commitment to elevating customer outcomes to the next level.

“The acquisition late last year brought together two long-trusted companies with highly complementary capabilities,” Elevaris Medical Devices CEO Richard Zrebiec said. “Today, as we complete integration, we believe operating under one brand demonstrates our combined commitment to our customers’ success.”

As the newly branded company, Elevaris Medical Devices will serve medical device companies in an unrivaled capacity. The unified team of engineering, design, and development experts is invested in applying its knowledge and product perspective to provide value-driven design, development, and production solutions that support customers’ success.

“From concept, to design and development, through manufacturing, we are qualified to support our customers in their quest to develop next-generation medical devices that enable the future of healthcare and improve global health,” Zrebiec stated. “Elevaris Medical Devices has the capability to be the preferred partner to drive a new era of precision medical device development and manufacturing.”

Elevaris Medical Devices is a (CDMO) for multi-national healthcare companies, global OEMs, and emerging technology companies. It manufactures made-to-spec procedural needles and specializes in manufacturing precision micro-components, complex tubular components, and sub-assemblies for the medical device industry. The company also distributes a wide range of complementary pharmaceutical products, surgical instruments, and medical supplies.

Elevaris Medical Devices has more than 300 employees in North America, the United Kingdom, and South Korea.